MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.739
EU - Europa 7.718
AS - Asia 7.051
SA - Sud America 876
OC - Oceania 521
AF - Africa 317
Continente sconosciuto - Info sul continente non disponibili 11
Totale 33.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.203
GB - Regno Unito 2.923
CN - Cina 1.569
SG - Singapore 1.457
IT - Italia 1.009
HK - Hong Kong 823
DE - Germania 795
BR - Brasile 665
SE - Svezia 628
PH - Filippine 530
AU - Australia 478
TR - Turchia 440
CA - Canada 411
VN - Vietnam 380
RU - Federazione Russa 332
FR - Francia 315
IR - Iran 282
UA - Ucraina 275
FI - Finlandia 273
IN - India 198
KR - Corea 179
PK - Pakistan 163
ID - Indonesia 149
IE - Irlanda 138
JP - Giappone 130
NL - Olanda 124
BG - Bulgaria 117
MY - Malesia 112
ES - Italia 104
PL - Polonia 104
GR - Grecia 97
ZA - Sudafrica 86
TW - Taiwan 85
IL - Israele 77
SA - Arabia Saudita 76
AR - Argentina 73
MA - Marocco 68
BE - Belgio 67
MX - Messico 66
AT - Austria 59
TH - Thailandia 51
LK - Sri Lanka 44
NP - Nepal 44
NZ - Nuova Zelanda 42
RO - Romania 42
NO - Norvegia 40
GE - Georgia 39
EC - Ecuador 36
JO - Giordania 36
IQ - Iraq 34
BD - Bangladesh 33
KE - Kenya 33
LT - Lituania 33
LV - Lettonia 32
CH - Svizzera 31
EE - Estonia 28
CZ - Repubblica Ceca 27
CO - Colombia 26
EG - Egitto 24
PT - Portogallo 23
HR - Croazia 22
CL - Cile 21
NG - Nigeria 18
AE - Emirati Arabi Uniti 17
HU - Ungheria 17
SI - Slovenia 17
SK - Slovacchia (Repubblica Slovacca) 17
BZ - Belize 14
PE - Perù 14
UG - Uganda 13
OM - Oman 12
TN - Tunisia 12
VE - Venezuela 12
UZ - Uzbekistan 11
PY - Paraguay 10
DK - Danimarca 9
MU - Mauritius 9
BH - Bahrain 8
CY - Cipro 8
DZ - Algeria 8
LB - Libano 8
BO - Bolivia 7
ET - Etiopia 7
KZ - Kazakistan 7
LY - Libia 7
PR - Porto Rico 7
UY - Uruguay 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
MO - Macao, regione amministrativa speciale della Cina 6
MV - Maldive 6
PA - Panama 6
CR - Costa Rica 5
GY - Guiana 5
LU - Lussemburgo 5
MW - Malawi 5
PS - Palestinian Territory 5
QA - Qatar 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
Totale 33.146
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Ashburn 1.447
Santa Clara 1.286
Woodbridge 1.142
Singapore 908
Chandler 839
Houston 824
Hong Kong 737
Seattle 684
Wilmington 655
Cambridge 590
Jacksonville 505
Dearborn 428
Ann Arbor 404
Nyköping 401
Hefei 370
London 335
Beijing 324
Los Angeles 278
Chicago 248
Modena 227
New York 224
Frankfurt am Main 198
Redwood City 183
Munich 180
San Diego 178
Helsinki 161
Izmir 152
Ho Chi Minh City 125
Shanghai 118
Princeton 116
Sofia 113
Salt Lake City 107
Melbourne 104
Seoul 104
Hanoi 103
Council Bluffs 102
Eugene 96
Moscow 93
Dallas 90
The Dalles 88
Jakarta 79
Dublin 76
Milan 73
Manchester 69
Buffalo 66
Sydney 64
Istanbul 60
São Paulo 60
Bremen 59
Brisbane 59
Ottawa 59
Tokyo 59
Elk Grove Village 52
Bologna 50
Columbus 50
Phoenix 48
San Jose 47
Warsaw 47
Falls Church 46
Taipei 46
Paris 45
Tampa 44
Liverpool 43
Athens 42
Quezon City 38
Brussels 37
Des Moines 37
Fremont 37
Tehran 37
Casablanca 35
Johannesburg 35
Colombo 34
Dong Ket 34
Islamabad 34
Denver 33
Montreal 33
Kuala Lumpur 32
Karachi 31
Perth 31
Stockholm 31
Birmingham 30
Lahore 30
Manila 30
Riyadh 30
Toronto 30
Cebu City 29
Atlanta 28
Boston 28
Brooklyn 28
Davao City 28
Lancaster 28
Norwalk 28
Riga 28
Rome 28
Sterling 28
Vienna 27
Nanjing 26
Greenwich 25
Totale 21.102
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.672
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 624
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 586
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 582
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 479
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 455
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 450
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 432
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 387
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 360
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 358
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 355
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 354
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 345
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 336
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 335
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 328
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 327
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 326
Empathic attitudes among nursing students: a preliminary study 325
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 322
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 320
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 315
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 311
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 306
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 305
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 300
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 295
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 292
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 291
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 291
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 273
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 266
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 266
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 263
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 261
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 260
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 260
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 258
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 257
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 256
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 256
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 255
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 255
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 255
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 254
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 252
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 250
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 249
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 249
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 247
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 246
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 245
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 244
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 242
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 240
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 239
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 237
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 237
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 237
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 236
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 236
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 233
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 233
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 230
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 229
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 227
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 224
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 224
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 222
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 216
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 214
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 213
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 210
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 207
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 206
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 205
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 203
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 200
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 199
Twenty-years experience with de novo metastatic breast cancer 194
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 192
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 189
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 189
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 185
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 184
I tumori nelle provincie di Parma, Reggio Emilia, Modena 182
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 178
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 177
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 176
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 172
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 171
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 165
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 164
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 157
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 150
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 149
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 145
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 144
Totale 32.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.462 0 0 0 0 0 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/20265.223 658 424 690 1.193 1.679 579 0 0 0 0 0 0
Totale 33.645